
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **CPB1 (Carboxypeptidase B1)**: Typically associated with pancreatic function, but its presence in breast cancer may indicate a role in tumor microenvironment or cancer cell metabolism.<br>- **IGFBP5 (Insulin-like Growth Factor Binding Protein 5)**: Involved in cell growth, apoptosis, and has been implicated in breast cancer progression.<br>- **GRIA2 (Glutamate Ionotropic Receptor AMPA Type Subunit 2)**: Generally associated with neural signaling, but its expression in cancer can be linked to cell signaling pathways.<br>- **GDF15 (Growth Differentiation Factor 15)**: A stress response cytokine often upregulated in cancer, including breast cancer, and associated with tumor progression.<br>- **GATA3 (GATA Binding Protein 3)**: A transcription factor crucial for luminal cell differentiation in the breast and a well-known marker for luminal breast cancer.<br>- **ESR1 (Estrogen Receptor 1)**: A key marker for hormone receptor-positive breast cancer, indicating luminal subtype.<br><br>### Step 2: List the Key Cell Type Markers<br>- **GATA3**: As mentioned, a critical marker for luminal epithelial cells in the breast.<br>- **ESR1**: Indicates estrogen receptor-positive luminal epithelial cells.<br>- **AGR3 (Anterior Gradient 3)**: Associated with secretory epithelial cells in the breast.<br>- **SCGB3A1 (Secretoglobin Family 3A Member 1)**: Often expressed in secretory epithelial cells.<br>- **KRTCAP2 (Keratinocyte Associated Protein 2)**: Related to epithelial cell function.<br>- **CCND1 (Cyclin D1)**: Involved in cell cycle regulation, often overexpressed in luminal breast cancer.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer scRNA-seq, we can confirm that markers like GATA3, ESR1, and CCND1 are strongly associated with luminal epithelial cells in breast tissue.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of GATA3, ESR1, and other epithelial markers, the most probable general cell type is **luminal epithelial cells** of the breast.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal A Subtype**: Characterized by high expression of ESR1 and GATA3, typically associated with a better prognosis.<br>2. **Luminal B Subtype**: Also expresses ESR1 and GATA3 but with higher proliferation markers like CCND1.<br>3. **Normal-like Luminal Cells**: Express similar markers but are less proliferative and more differentiated.<br><br>Given the presence of ESR1, GATA3, and CCND1, the most likely subtype is **Luminal B**, as it aligns with the expression of proliferation markers.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of luminal epithelial cells. The expression of key markers such as GATA3, ESR1, and CCND1 indicates a luminal B subtype, which is characterized by hormone receptor positivity and higher proliferation rates compared to luminal A.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**:<br>   - The key markers used for annotation, such as GATA3, ESR1, and CCND1, are present in the provided marker list.<br>   - These markers are well-known and strongly associated with luminal epithelial cells in breast tissue, particularly in the context of breast cancer.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The analysis does not indicate the presence of multiple distinct cell types strongly supported by several high-ranking markers. The markers used are consistent with a single cell type, specifically luminal epithelial cells.<br>   - The annotation correctly identifies the luminal B subtype based on the expression of proliferation markers like CCND1, which aligns with the provided marker list and known literature.<br><br>Overall, the annotation is well-supported by the marker list and aligns with known biological characteristics of luminal epithelial cells in breast cancer.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">luminal epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Luminal A Subtype</li><li>Luminal B Subtype</li><li>Normal-like Luminal Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the key markers associated with luminal epithelial cells in breast cancer, particularly the luminal B subtype. The analysis correctly identifies GATA3, ESR1, and CCND1 as critical markers, which are well-documented in the literature as being indicative of luminal breast cancer subtypes. This suggests a high level of scientific accuracy in the annotations.<br><br>The annotation process shows a balanced consideration of multiple markers, as it does not overly focus on a single marker but rather integrates several key markers to arrive at the final cell type classification. The use of databases and literature to cross-reference and validate the marker associations further strengthens the reliability of the annotations.<br><br>The analysis captures the general picture of the cell populations by identifying the main cell type (luminal epithelial cells) and further distinguishing between subtypes (Luminal A, Luminal B, and Normal-like Luminal Cells). This comprehensive view is crucial for understanding the heterogeneity within breast cancer tissues.<br><br>However, there are a few areas where the analysis could be improved. While the annotation identifies the luminal B subtype based on proliferation markers like CCND1, it could have provided more detail on how other markers in the list contribute to this classification. Additionally, the analysis could have considered the rank of the markers more explicitly, as the order of marker appearance might suggest their relative importance.<br><br>Overall, the annotation is scientifically accurate, well-balanced, and provides a comprehensive view of the cell types present, with minor areas for improvement in detailing the contribution of all markers and considering their rank.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    